Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

Background and Rationale

Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event for patients with melanoma. In melanoma treatment centres around the world, patients without demonstrated pelvic LN disease receive 1 of 3 strategies of management in relatively equal proportions (Pasquali, Spillane et al. 2012):

i. Inguinal Lymphadenectomy (IL) ii. Ilio-inguinal Lymphadenectomy (I-IL) iii. Variable use of either IL or I-IL surgery.

Some larger melanoma centres have an institutional policy that all patients have either IL or I-IL for metastatic inguinal node involvement. Nearly all centres would agree that patients with pelvic LN involvement without distant metastatic disease should have I-IL.

Study Objectives This study aims to provide a more rational evidence base for appropriate management for metastatic melanoma in the groin LNs, through assessing the effect of the addition of ipsilateral pelvic lymphadenectomy on patient disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), morbidity, and quality of life. In addition, the study will clarify the reliability of PET (Positron Emission Tomography) / CT (Computed Tomography) scans for staging pelvic LNs, clarify morbidity differences between the operations in a balanced cohort, evaluate any health economic benefits of I-IL over IL and provide a tissue and serum resource to be used to identify biological markers of recurrence and progression after inguinal metastases.

Study Hypothesis There will be no significant difference in DFS between patients having IL or I-IL, conditional on PET/CT scan showing no evidence of pelvic disease at the time of diagnosis of groin LN metastatic melanoma.

Study Population The aim is to recruit 634 patients in 5 years who are 15 years or older with cytologically or histologically confirmed metastatic melanoma in inguinal LNs (H&E & IHC); specifically with no evidence of pelvic node involvement or distant spread of melanoma clinically or on PET/CT staging scans. To be eligible patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 at randomisation.

Study Treatments Eligible patients will be randomised 1:1 to undergo an IL or I-IL.

Study Design This is an international, multi-centre, phase III, non-inferiority, prospective, randomised clinical trial.

Inclusion criteria

Patients may be included in the study only if they meet all of the following criteria:

• Must be 15 and above.
• Have primary cutaneous melanoma or if the patient presents with stage III melanoma with no known primary tumour then a thorough search for the primary should be documented (including perineal and perianal areas)
• Life expectancy of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI
• Must have one or multiple inguinal node(s) involved, histologically or cytologically proven as metastatic melanoma. This can can be detected:

• At the time of diagnosis;
• Or by Ultrasound detection;
• Or later after relapse when no Sentinel Node Biopsy (SNB) was performed at the time of primary tumour management;
• Or as a result of SNB;
• Or at the time of regional recurrence after "false negative" SNB;
• Absent distant disease clinically and on PET/CT scan. (Patients must have NO further distant disease or visceral metastases)
• ECOG performance status must be between 0 to 2 at randomisation
• Whole body PET/CT scan, specifically stating there is NO evidence of pelvic lymph node involvement prior to randomisation and a CT Brain or MRI Brain scan. Scans must be performed within 6 weeks prior to randomisation.
• Able to provide written, informed consent
• Willing to return to the centre for follow up examinations and procedures, as outlined in the protocol.
• All patients must be randomised and undergo lymphadenectomy surgery no more than 120 days following diagnosis of inguinal LN involvement

Exclusion criteria

• Distant metastatic disease on clinical examination or staging imaging (CT/MRI brain or whole body PET/CT scan). Scans must be performed within 6 weeks prior to randomisation
• Pelvic LN involvement on SNB or PET/CT scan suggestive of metastatic disease in the pelvis - criteria for diagnosis include normal size or enlarged lymph nodes (> 1 cm) with increased FDG activity on PET (SUV >3). If there are enlarged, necrotic lymph nodes FDG activity on PET is not required to be present. If unsure central review should be sought.
• Bilateral inguinal lymph node involvement
• Patients with a history of major pelvic surgery and / or regional radiotherapy at any time in the past
• Requiring planned radiotherapy following surgery due to macroscopic, bulky and matted nodes.
• Unfit for General Anaesthesia
• Melanoma-related operative procedures not corresponding to criteria described in the protocol
• Patients with prior cancers, except:

• those with a thin <=1 mm, regionally unrelated melanoma > 5 years ago
• those with a good prognosis regionally unrelated cancer (>90% probability of 10 years disease specific survival)
• other cancers diagnosed more than five years ago with no evidence of disease recurrence within this time
• successfully treated basal cell and squamous cell skin carcinoma
• carcinoma in-situ of the cervix
• 1 episode of in transit melanoma > 3 years ago
• A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol
• Positive urine pregnancy test for women of childbearing potential (+/-7 days of randomisation onto the trial)